Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024
Eurosurveillance·
- DOI
- 10.2807/1560-7917.es.2025.30.10.2400252
- PMID
- —
- PMCID
- —
- OpenAlex
- W4408459014
- Study type
- Systematic review
- Publisher
- European Centre for Disease Control and Prevention (ECDC)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Tracking these genetic trends assists regulatory bodies in updating therapeutic protocols and withdrawing medications that no longer align with current viral profiles.
Structured evidence summary
Research question
What effect do circulating SARS-CoV-2 genetic alterations have on the clinical utility of approved monoclonal antibodies and antiviral agents?
Study design
Researchers compiled and analyzed 298 peer-reviewed and preprint articles spanning four major biomedical databases to evaluate drug-virus interactions.
Population and setting
The assessment centers on fourteen recognized viral strains operating within European Union and European Economic Area regions.
Main findings
Distinct enzymatic and structural protein changes corresponded with lowered treatment responsiveness, notably diminishing antibody neutralization across multiple Omicron descendants. Several direct-acting antivirals also demonstrated variable susceptibility declines tied to specific polymerase modifications.
Public-health relevance
Tracking these genetic trends assists regulatory bodies in updating therapeutic protocols and withdrawing medications that no longer align with current viral profiles.
Important limitations
This summary is constrained to the supplied single-article abstract and metadata, requiring the original manuscript for decision-grade interpretation.
GIDS interpretation
This work serves as a thematic reference linking viral evolution to pharmacological vulnerability, facilitating academic indexing on treatment resistance without implying active epidemiological tracking.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.